Skip to content

Study · Ex vivo tissue · 1998

9 results

Specific receptors for synthetic GH secretagogues in the human brain and pituitary gland.

Muccioli G, Ghè C, Ghigo MC, Papotti M, Arvat E, Boghen MF, Nilsson MH, Deghenghi R, Ong H, Ghigo E

The Journal of endocrinology1 Apr 1998Cited by 94 (Europe PMC)

PMID9614363 (opens in a new tab)DOI10.1677/joe.0.1570099 (opens in a new tab)PepBankPUB-09614363
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueActivity measurement

    In human pituitary and hypothalamic membranes, MK 0677 dose-dependently displaced labeled Tyr-Ala-hexarelin binding.

    In plain wordsIn lab tests, MK 0677 displaced the labeled ligand from human pituitary and hypothalamic membranes as its dose increased.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    DecreaseRadioligand binding displacement
    Study

    humann: not reported in source

    pituitary and hypothalamic membranes
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The binding of 125I-labelled Tyr-Ala-hexarelin to pituitary and hypothalamic membranes was displaced in a dose-dependent manner by different unlabelled synthetic peptidyl (Tyr-Ala-hexarelin, GHRP2, hexarelin, GHRP6) and non-peptidyl (MK 0677) sGHS.
    1 context sentence
    Summary · context
    In vitro studies have been performed to demonstrate and characterize specific binding sites for synthetic GH secretagogues (sGHS) on membranes from pituitary gland and different human brain regions.
  2. 02LabIn vitro (cell-free)Activity measurement

    In human pituitary and hypothalamic membranes, unlabelled GHRP‑2 displaced binding of radiolabelled Tyr-Ala-hexarelin in a dose-dependent manner.

    In plain wordsIn lab tests on human pituitary and brain membranes, GHRP‑2 competed with a labelled GH secretagogue for its binding sites.

    Peptide
    GHRP-2
    Outcome
    DecreaseDisplacement of radioligand binding by GHRP-2
    Study

    humann: not reported in source

    Membranes from human pituitary gland and brain regions
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The binding of 125I-labelled Tyr-Ala-hexarelin to pituitary and hypothalamic membranes was displaced in a dose-dependent manner by different unlabelled synthetic peptidyl (Tyr-Ala-hexarelin, GHRP2, hexarelin, GHRP6) and non-peptidyl (MK 0677) sGHS.
    1 context sentence
    Summary · context
    In vitro studies have been performed to demonstrate and characterize specific binding sites for synthetic GH secretagogues (sGHS) on membranes from pituitary gland and different human brain regions.
  3. 03LabIn vitro (cell-free)Activity measurement

    In human pituitary and hypothalamic membranes, unlabelled GHRP‑6 displaced binding of radiolabelled Tyr-Ala-hexarelin in a dose-dependent manner.

    In plain wordsIn lab tests on human pituitary and brain membranes, GHRP‑6 competed with a labelled GH secretagogue for its binding sites.

    Peptide
    GHRP-6
    Outcome
    DecreaseDisplacement of radioligand binding by GHRP-6
    Study

    humann: not reported in source

    Membranes from human pituitary gland and brain regions
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The binding of 125I-labelled Tyr-Ala-hexarelin to pituitary and hypothalamic membranes was displaced in a dose-dependent manner by different unlabelled synthetic peptidyl (Tyr-Ala-hexarelin, GHRP2, hexarelin, GHRP6) and non-peptidyl (MK 0677) sGHS.
    1 context sentence
    Summary · context
    In vitro studies have been performed to demonstrate and characterize specific binding sites for synthetic GH secretagogues (sGHS) on membranes from pituitary gland and different human brain regions.
  4. 04LabIn vitro (cell-free)Activity measurement

    In human pituitary and hypothalamic membranes, unlabelled hexarelin displaced binding of radiolabelled Tyr-Ala-hexarelin in a dose-dependent manner.

    In plain wordsIn lab tests on human pituitary and brain membranes, hexarelin competed with a labelled GH secretagogue for its binding sites.

    Peptide
    Hexarelin
    Outcome
    DecreaseDisplacement of radioligand binding by hexarelin
    Study

    humann: not reported in source

    Membranes from human pituitary gland and brain regions
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The binding of 125I-labelled Tyr-Ala-hexarelin to pituitary and hypothalamic membranes was displaced in a dose-dependent manner by different unlabelled synthetic peptidyl (Tyr-Ala-hexarelin, GHRP2, hexarelin, GHRP6) and non-peptidyl (MK 0677) sGHS.
    1 context sentence
    Summary · context
    In vitro studies have been performed to demonstrate and characterize specific binding sites for synthetic GH secretagogues (sGHS) on membranes from pituitary gland and different human brain regions.

Studies that did not test the peptide alone5

In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Hexarelin.

  1. 05LabNot a test of Hexarelin aloneIn vitro (cell-free)Activity measurement

    Specific binding sites for 125I-labelled Tyr-Ala-hexarelin were found mainly in human pituitary and hypothalamus membranes, and also in choroid plexus, cortex, hippocampus and medulla oblongata, with no sex-related differences.

    In plain wordsIn lab tests, binding sites for a labelled hexarelin analogue were found mainly in human pituitary and hypothalamus, and in some other brain areas.

    Peptide
    Hexarelin
    Outcome
    Not applicableTyr-Ala-hexarelin binding sites by region
    Study

    humann: not reported in source

    Membranes from human pituitary gland and brain regions
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    Specific binding sites for 125I-labelled Tyr-Ala-hexarelin were detected mainly in membranes isolated from pituitary gland and hypothalamus, but they were also present in other brain areas such as choroid plexus, cerebral cortex, hippocampus and medulla oblongata with no sex-related differences.
    1 context sentence
    Summary · context
    In vitro studies have been performed to demonstrate and characterize specific binding sites for synthetic GH secretagogues (sGHS) on membranes from pituitary gland and different human brain regions.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  2. 06LabNot a test of Hexarelin aloneIn vitro (cell-free)Activity measurement

    Negligible binding of 125I-labelled Tyr-Ala-hexarelin was found in the thalamus, striatum, substantia nigra, cerebellum and corpus callosum.

    In plain wordsIn lab tests, a labelled hexarelin analogue bound very little in several human brain areas, including the thalamus and cerebellum.

    Peptide
    Hexarelin
    Outcome
    No significant changeTyr-Ala-hexarelin binding in other brain regions
    Study

    humann: not reported in source

    Membranes from human pituitary gland and brain regions
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    In contrast, negligible binding was found in the thalamus, striatum, substantia nigra, cerebellum and corpus callosum.
    2 context sentences
    Summary · context
    Specific binding sites for 125I-labelled Tyr-Ala-hexarelin
    Summary · context
    In vitro studies have been performed to demonstrate and characterize specific binding sites for synthetic GH secretagogues (sGHS) on membranes from pituitary gland and different human brain regions.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  3. 07LabNot a test of Hexarelin aloneIn vitro (cell-free)Activity measurement

    Binding of 125I-labelled Tyr-Ala-hexarelin to membrane sites was saturable and reversible, and depended on incubation time and buffer pH.

    In plain wordsIn lab tests, a labelled hexarelin analogue bound to membrane sites in a saturable and reversible way.

    Peptide
    Hexarelin
    Outcome
    Not applicableSaturability and reversibility of Tyr-Ala-hexarelin binding
    Study

    humann: not reported in source

    Membranes from human pituitary gland and brain regions
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    The binding of 125I-labelled Tyr-Ala-hexarelin to membrane-binding sites is a saturable and reversible process, depending on incubation time and pH of the buffer.
    1 context sentence
    Summary · context
    In vitro studies have been performed to demonstrate and characterize specific binding sites for synthetic GH secretagogues (sGHS) on membranes from pituitary gland and different human brain regions.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  4. 08LabNot a test of Hexarelin aloneIn vitro (cell-free)Activity measurement

    Scatchard analysis showed a finite number of binding sites for Tyr-Ala-hexarelin in hypothalamus and pituitary, with Kd values of 1.5 and 2.1 x 10(-9) mol/l.

    In plain wordsIn lab tests, a labelled hexarelin analogue bound human hypothalamus and pituitary membranes with high affinity.

    Peptide
    Hexarelin
    Outcome
    Not applicableKd of Tyr-Ala-hexarelin binding
    Study

    humann: not reported in source

    Membranes from human pituitary gland and brain regions
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Measurements

    Kd
    1.5 x 10(-9) mol/l
    hypothalamus
    Kd
    2.1 x 10(-9) mol/l
    pituitary gland

    Source sentences

    Summary
    Scatchard analysis of the binding revealed a finite number of binding sites in the hypothalamus and pituitary gland with a dissociation constant (Kd) of (1.5 +/- 0.3) x 10(-9) and (2.1 +/- 0.4) x 10(-9) mol/l respectively.
    2 context sentences
    Summary · context
    The binding of 125I-labelled Tyr-Ala-hexarelin to membrane-binding sites is a saturable and reversible process, depending on incubation time and pH of the buffer.
    Summary · context
    In vitro studies have been performed to demonstrate and characterize specific binding sites for synthetic GH secretagogues (sGHS) on membranes from pituitary gland and different human brain regions.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  5. 09LabNot a test of Hexarelin aloneIn vitro (cell-free)Mechanism

    Receptor activity was sensitive to trypsin and phospholipase C digestion, which suggests that protein and phospholipids are essential for binding of Tyr-Ala-hexarelin.

    In plain wordsIn lab tests, digesting protein or fat parts of the membrane stopped a labelled hexarelin analogue from binding.

    Peptide
    Hexarelin
    Outcome
    DecreaseEnzyme sensitivity of Tyr-Ala-hexarelin binding
    Study

    humann: not reported in source

    Membranes from human pituitary gland and brain regions
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    Receptor activity is sensitive to trypsin and phospholipase C digestion, suggesting that protein and phospholipids are essential for the binding of 125I-labelled Tyr-Ala-hexarelin.
    1 context sentence
    Summary · context
    In vitro studies have been performed to demonstrate and characterize specific binding sites for synthetic GH secretagogues (sGHS) on membranes from pituitary gland and different human brain regions.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 5Current

    14 Oct 2026, 01:46 UTC

    Study data updated · source update from Europe PMC

  2. Version 4

    13 Oct 2026, 21:44 UTC

    Study results updated

  3. Versions 2 to 3

    13 Oct 2026, 16:31 UTC

    The same notice was added 2 times, first on 13 Oct 2026, 16:31 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  4. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.